ArticleEFSA journal. European Food Safety Authority2026
Assessment of genetically modified soybean GMB151 × DAS-44406-6 (application GMFF-2024-21774, EFSA-Q-2024-00330).
Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of genetically modified soybean GMB151 × DAS-44406-6 (application GMFF-2024-21774, EFSA-Q-2024-00330).EFSA journal. European Food Safety Authority · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically modified soybean GMB151 × DAS-44406-6 was developed by crossing to combine two single events: GMB151 and DAS-44406-6. The two-event stack soybean expresses the Cry14Ab-1, HPPD-4, PAT, AAD-12 and 2mEPSPS proteins to confer herbicide tolerance and resistance to plant parasitic nematodes. The GMO Panel previously assessed the two single soybean events and did not identify safety concerns. No new data on the single soybean events were identified that could lead to modification of the original conclusions on their safety. The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate that the combination of the single soybean events and of the newly expressed proteins in the two-event stack soybean does not give rise to food and feed safety and nutritional concerns. The GMO Panel concludes that two-event stack soybean, as described in this application, is as safe as the comparator and non-GM reference soybean varieties tested and no post-market monitoring of food/feed is considered necessary. In the case of accidental release of GM two-event stack soybean material into the environment, this would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of soybean GMB151 × DAS-44406-6. Post-market monitoring of food/feed is not considered necessary. The GMO Panel concludes that two-event stack soybean is as safe as its comparator and the tested non-GM reference varieties with respect to potential effects on human and animal health and the environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.